What acid-base disturbance is typically seen with the treatment of sulfamylon (mafenide sodium)?

The use of sulfamylon (mafenide sodium) as a topical agent, particularly in burn management, can lead to a specific acid-base disturbance known as hyperchloremic metabolic acidosis. This occurs due to the systemic absorption of the drug, which inhibits carbonic anhydrase activity. As a result, there is reduced bicarbonate reabsorption and decreased carbon dioxide transport, ultimately shifting the acid-base balance.

Hyperchloremic metabolic acidosis is characterized by a primary decrease in bicarbonate concentration, leading to a compensatory respiratory response, which may ultimately result in lowered pH levels. In cases where sulfamylon is used extensively, particularly in patients with large burn areas, this type of acidosis may become more pronounced, making it a relevant consideration during the management of these patients.

Understanding this particular disturbance helps in both monitoring and treating patients receiving sulfamylon therapy, ensuring proper management of their acid-base status. In contrast, the other options do not directly correlate with the known effects of mafenide sodium treatment.